Acadia Pharmaceuticals Inc (ACAD) SEC 13F Holdings (Q2 2026): Institutional Buyers & Sellers

ACAD ranks #1773 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

ACAD is a top-conviction position for Palo Alto Investors LP — at 10.0% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ACAD belongs to Baker Bros. Advisors LP, but the position matters far more to Palo Alto Investors LP, who has 10.0% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Farther Finance Advisors, LLC has added to its ACAD position for two straight quarters, increasing it by $170.8K to reach $181.8K today.

State of Alaska, Department of Revenue has trimmed its ACAD position for two straight quarters, cutting it by $1.1M while still holding $1.1M.

ACAD is down 3% today, but institutions show net buying of $246.4M this quarter — a divergence between today's price move and the underlying institutional flow.

ACAD posted net income of $380.5M over the trailing twelve months, and currently trades at a P/E of 8.5.

• Profitable — net income of $380.5M over the trailing twelve months
• Revenue grew 11.8% year over year
• Net income improved year over year, from $222.2M to $380.5M
• Generated $109.8M in positive operating cash flow
• Current ratio of 3.83x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.27x equity — within a conventional range